Genetics Generation Advancement Corp is a Taiwan-based company mainly engaged in the development and introduction of digital data management systems for genetic testing, biology, chemistry and material consulting. Genetic testing services include pre-pregnancy and pregnancy testing, newborn testing, hereditary health and cancer screening and adult health management, and comprehensive genetic testing. Molecular digital services include software and database products, laboratory electronic management systems, enterprise quality management systems, scientific professional databases, scientific consulting services.

Employees

104

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-19	NT$38.30	+0.79%	97,350
26-10-19	NT$38.00	-2.06%	60,956
26-10-16	NT$38.80	+1.31%	12,460
26-10-15	NT$38.30	-1.03%	88,242
26-10-14	NT$38.70	-0.77%	19,344

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-10-20			5-day change	1st Jan Change
38.30 ^TWD	+0.79%		-1.79%	-19.28%

08-13	Genetics Generation Advancement Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-14	Genetics Generation Advancement Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	1.07B 32.85M 29.24M 27.1M 24.56M 46.15M 3.11B 46.92M 325M 128M 1.63B 123M 121M 5.2B	P/E 2024	33.6x	P/E 2025	62.3x
Enterprise Value	745M 22.8M 20.3M 18.81M 17.04M 32.03M 2.16B 32.57M 226M 88.66M 1.13B 85.53M 83.75M 3.61B	EV / Sales 2024	2.2x	EV / Sales 2025	1.66x
Free-Float	62.11%	Yield 2024	2.69%	Yield 2025	-

08-13	Genetics Generation Advancement Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-14	Genetics Generation Advancement Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	Genetics Generation Advancement Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-12	Genetics Generation Advancement Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-11	Genetics Generation Advancement Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-14	Genetics Generation Advancement Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-26	Genetics Generation Advancement Corp. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-09	Genetics Generation Advancement Corp. announces Annual dividend, payable on October 31, 2025	CI
24-11-13	Genetics Generation Advancement Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-14	Genetics Generation Advancement Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-14	Genetics Generation Advancement Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-03-25	Genetics Generation Advancement Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-04	Genetics Generation Advancement Corp. announces Annual dividend, payable on October 25, 2024	CI

22-08-15	Genetics Generation Advancement : Announcement of the record date of cash dividend	PU
22-08-05	Genetics Generation Advancement : Announcement of the Partial Correction of the Company's 2021 Annual Report	PU
22-08-03	Genetics Generation Advancement : To announce that 2022Q2 Consolidated Financial Statement approved by the Board of Directors	PU
22-03-17	Genetics Generation Advancement : Announce the release of non-competition restriction on managerial officer by the Board of Directors	PU
22-03-17	Genetics Generation Advancement : Announce the change of the company’s Spokesperson,Financial Officer,Accounting Officer and Corporate Governance Officer	PU

Genetics Generation Advancement Corp. Stock

Stocks

4160

TW0004160007

Biotechnology & Medical Research

Valuation: Genetics Generation Advancement Corp.

Chart: Genetics Generation Advancement Corp.

Latest news: Genetics Generation Advancement Corp.

Press Releases: Genetics Generation Advancement Corp.

Quotes and Performance

Price Extremes

Managers and Directors: Genetics Generation Advancement Corp.

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

1 day	+0.79%
1 week	-1.79%
Current month	-2.05%
1 month	-2.17%
3 months	+0.75%
6 months	-10.07%
Current year	-19.28%

1 week	37.35	40.2
1 month	37.35	40.35
Current year	36.73	54.31
1 year	36.73	55.93
3 years	33.55	143.74
5 years	19.91	143.74
10 years	16.79	143.74

Manager	Title	Age	Since
Ching Yuan Kang CEO	Chief Executive Officer	-	2024-03-04
Yu Chun Hsiao DFI	Director of Finance/CFO	-	2023-12-31
Tai Sheng Chang CTO	Chief Tech/Sci/R&D Officer	-	2010-02-28

Director	Title	Age	Since
Cheng Hsien Tsai BRD	Director/Board Member	-	2010-12-14
Wen Cheng Chang BRD	Director/Board Member	-	2011-10-31
Han Tung Chang CHM	Chairman	-	2011-10-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENETICS GENERATION ADVANCEMENT CORP.	+0.79%	-1.79%	-25.14%	+10.56%	32.76M
WUXI APPTEC CO., LTD.	+0.79%	-6.46%	+52.86%	+71.34%	65.83B
LONZA GROUP AG	+1.92%	+10.35%	+13.02%	+87.74%	51.87B
ARGENX SE	+6.91%	+8.57%	+6.88%	+72.12%	51.2B
IQVIA HOLDINGS INC.	+1.01%	+2.69%	+26.24%	+45.20%	43.76B
BEONE MEDICINES AG	+3.25%	+9.31%	+19.77%	+130.97%	42.09B
REVOLUTION MEDICINES, INC.	+7.85%	+3.72%	+261.89%	+598.80%	39.04B
CELLTRION, INC.	-0.40%	+9.42%	+18.44%	+59.06%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+3.84%	-4.94%	+42.35%	+8.92%	25.2B
GENMAB A/S	+2.36%	+5.34%	+30.98%	+26.07%	22.8B
Average	+2.85%	+0.36%	+44.73%	+111.08%	37.58B
Weighted average by Cap.	+3.03%	+0.62%	+50.85%	+124.09%

	2024	2025
Net sales	662M 20.26M 18.04M 16.72M 15.15M 28.47M 1.92B 28.94M 201M 78.8M 1B 76.01M 74.43M 3.2B	603M 18.46M 16.44M 15.23M 13.8M 25.94M 1.75B 26.37M 183M 71.8M 915M 69.26M 67.82M 2.92B
Net income	54.7M 1.67M 1.49M 1.38M 1.25M 2.35M 159M 2.39M 16.58M 6.51M 83.02M 6.28M 6.15M 265M	21.37M 654K 582K 540K 489K 919K 61.99M 935K 6.48M 2.54M 32.44M 2.45M 2.4M 103M
Net Debt	-373M -11.41M -10.15M -9.41M -8.53M -16.02M -1.08B -16.29M -113M -44.35M -565M -42.78M -41.9M -1.8B	-328M -10.05M -8.94M -8.29M -7.51M -14.12M -952M -14.35M -99.46M -39.07M -498M -37.69M -36.91M -1.59B